Akebia Therapeutics, Inc.
Public company- Headquarters
- WALTHAM, Massachusetts
- Ticker
- AKBA
- CIK
- 0001517022
WARN notices since 2024
Workers affected since 2024
Executive changes, last 12 months
Last event
Workers affected over time
Cumulative workers in WARN notices since 2024
Not enough notices to chart yet.
Leadership
| Role and person | Since | Change |
|---|---|---|
| Senior Vice President and Chief Commercial OfficerNicholas Grund | Oct 14, 2026 | Departed |
Related companies
Same industry and state, with recent events.
- ENANTA PHARMACEUTICALS INC
CEO departs: Jay R. Luly, Ph.D.
- VERTEX PHARMACEUTICALS INC / MA
new member of the board of directors appointed: Daniel Brennan
- Ernexa Therapeutics Inc.
member of the Board appointed: Robert J. Spiegel, M.D.
- BRISTOL MYERS SQUIBB CO
WARN notice: Princeton, NJ
- Executive departure
Senior Vice President and Chief Commercial Officer departs: Nicholas Grund
Nicholas Grund, Senior Vice President and Chief Commercial Officer of Akebia Therapeutics, Inc., resigns the role, effective November 6, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Oct 14, 2026Role: Senior Vice President and Chief Commercial Officer
Only one public record so far. We add events as soon as a new filing lands; watch Akebia Therapeutics, Inc. to get them in your digest.
Last verified Nov 8, 2026